17,261 trials
Melanoma
Primary: Overall Response Rate (ORR) — 8.9; 4.7; 4.7; 6.8 Percentage of participants
Cannabis Use Disorder
Primary: Efficacy of Varenicline vs. Placebo for Reducing Total Number of Weekly Cannabis Use Sessions — 10.3; 11.6; 9.4; 11.7 number of weekly use sessions
Immunodeficiencies
Primary: Number of Participants With Successful Engraftment — 87; 5 Participants
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8 · Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8 · Clinical Stage III Esophageal Adenocarcinoma AJCC v8
Primary: Number of Patients With a Pathologic Complete Response — 2 Participants
Glaucoma, Open-Angle
Primary: Mean Intraocular Pressure — 21.8; 20.5; 23.4; 19.7 mmHg
Advanced Metastatic Cancer · Advanced Prostate Cancer
Primary: Clinical Benefit Rate (CBR) of Nivolumab With or Without Ipilimumab — 1; 18; 1; 1 Participants
Leukemia
Primary: Number of Participants With a Response to Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With…
Eosinophilic Gastritis · Eosinophilic Gastroenteritis
Primary: Percent Change in the Number of Eosinophils Per High Power Field in Gastric or Duodenal Mucosa From Baseline — -79; -92; -86; 9 Percentage of Change — p=<0.001
GLUT1DS1
Primary: Change in Ketosis (Beta-hydroxybutyrate Levels) — 3.82 mM
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome · Acute Myeloid Leukemia With Gene Mutations
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Leukemia
Primary: Overall Response (OR) Post Transplant — 1; 6; 0 Participants
Mixed Dyslipidemia
Primary: Percent Change From Baseline in Fasting TG at Week 24 — 7.55; -43.67; -49.01; -55.57 percentage change — p=<.0001
Autoimmune Disorder · Rheumatoid Arthritis · Systemic Lupus Erythematosus
Primary: The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE — 60.0; 33.3 Percentage of participants…
Influenza, Human
Primary: Safety Endpoint 1: Percentages of Subjects With Solicited Local and Systemic Adverse Events (AEs) — 32; 33; 32; 34 Participants
Hyperlipidemias
Primary: Change in Direct-measured LDL-C — -3.80; 2.95; 4.36; -1.70 mg/dL — p=0.0167